Trials / Completed
CompletedNCT07143513
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to characterize the safety profile of sotorasib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sotorasib | Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2025-08-11
- Primary completion
- 2025-12-07
- Completion
- 2025-12-07
- First posted
- 2025-08-27
- Last updated
- 2026-04-07
Locations
3 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07143513. Inclusion in this directory is not an endorsement.